Key clinical point: Treatment with 5α-reductase inhibitors (5ARIs) may delay disease progression in patients with local and low Gleason score prostate cancer.

Major finding: 5ARI treatment significantly reduced the total disease progression (odds ratio [OR], 0.61; P less than .0001), particularly for patients with local (OR, 0.56; P less than .00001) and low Gleason score (≤7) prostate cancer (OR, 0.63; P = .002). 5ARIs also prolonged progression-free survival (hazard ratio, 0.57; P = .04) for patients with prostate cancer.

Study details: A meta-analysis 10 studies including 2,277 patients with prostate cancer.

Disclosures: The study was funded by grants from the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, and the China Postdoctoral Science Foundation. The authors declared no conflicts of interest.